21282-91-7

Upstream product

• 71-43-2 benzene 
• 52240-15-0 β-(m-aminobenzoyl)propionic acid 
• 6328-00-3 4-(3-nitro-phenyl)-4-oxo-butyric acid 
• 2051-95-8 succinylbenzene 
• 90991-20-1 4-(3-nitro-phenyl)-4-oxo-butyric acid methyl ester 
• 52239-76-6 3-(m-Nitrophenyl)-6-oxo-1,4,5,6-tetrahydropyridazine 

Downstream Products

• 1304095-47-3 C₁₅H₁₃N₃O₂ 
• 1304095-44-0 C₁₇H₁₅N₃O 
• 1304095-42-8 C₁₇H₁₅N₃O₂ 
• 1304095-43-9 C₁₈H₁₇N₃O₂ 
• 1304095-53-1 C₁₇H₁₅N₃O₂ 
• 1304095-45-1 C₁₈H₁₇N₃O₃ 
• 1304095-39-3 C₁₂H₁₃N₃O 
• 1304095-50-8 C₁₈H₁₇N₃O₂ 
• 1304095-52-0 C₁₉H₂₀N₄O 
• 175437-08-8 2-{[3-(6-Oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenylamino]-methylene}-malonic acid diethyl ester 
• 14714-33-1 6-(3-acetylamino-phenyl)-4,5-dihydro-2H-pyridazin-3-one 

Relevant academic research and scientific papers

Synthesis of different substituted pyridazinone derivatives and their anticonvulsant activity

6-Phenyl(3'-imino-benzylidene)-2,3,4,5-tetrahydro pyridazin-3-one derivatives were synthesized from 6-(3'-aminophenyl)-2,3,4,5-tetrahydro pyridazin-3-one by reaction with different aldehydes. The respective pyridazinone was prepared by cyclization of appropriate β-(aminophenyl) propionic acid with hydrazine hydrate. The pyridazinone derivatives were tested for anticonvulsant activity by MES (maximal electro shock) method and found that few of them have shown significant anticonvulsant activity.

Syntheses and exploration of new biological activities in ethyl 6/7-substituted and 6, 7-disubstituted quinolin-4-one-3-carboxylates

Syntheses of a number of ethyl 1H, 4H-quinolin-4-one-3-carboxylates carrying substituted piperidinedione ring at position 6 (25 and 31-35), tetrahydrofuranone (37) or tetrahydropyridazinone ring (39) at position 7 and hydroxy and hydroxymethyl substituent

6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities

This paper reports on the synthesis and pharmacological activity of 6-aryl-4,5-dihydro-3(2H)-pyridazinone derivatives. The compounds exhibit an aggregation inhibiting action on human platelets in vitro and on rat platelets under ex vivo conditions, as wel